Notwithstanding promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from managed care entities. The insurers are typically erecting obstacles to reimbursement, like steep cost requirements and approval processes that limit consumer availabilit